Ep. 379 - Argenx M&A, AI giants and biopharma, catalyst scorecard

Argenx the tier-jumping European biotech, believes its proposed $2.2 billion purchase of Forte Biosciences will add a second multi-indication product upon which it can run the strategy that has made autoimmune drug Vyvgart efgartigimod alfa a blockbuster. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the deal and put it in the context of a new cohort of large-cap companies increasingly active in biotech M&A.The analysts also assess how recent releases from Anthropic, NVIDIA, Google, OpenAI and Amazon fit into biopharma R&D workflows — and with one another. Finally, they analyze the 1H26 clinical and regulatory catalyst scorecard, which therapies hit their milestones, which missed, and what’s next through year-end. This episode of the BioCentury This Week podcast has been brought to you by CBRE.View full story: https://www.biocentury.com/article/660296#BiotechMA #ArtificialIntelligence #DrugDevelopment #ClinicalTrials #Biopharma00:01 - Sponsor Message: CBRE01:57 - BioCentury AI Connector05:47 - Argenx Acquires Forte08:06 - Rise of Biotech Buyers13:12 - AI Giants' Tech Stack24:20 - Anthropic Enters Drug Development27:41 - 2026 CatalystTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text